Fresenius Medical Care AG & Co KGaA
XETRA:FME
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.13
42.25
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one FME stock under the Base Case scenario is 80.86 EUR. Compared to the current market price of 42.25 EUR, Fresenius Medical Care AG & Co KGaA is Undervalued by 48%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Fresenius Medical Care AG & Co KGaA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for FME cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Fresenius Medical Care AG & Co KGaA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Fresenius Medical Care AG & Co KGaA emerged as a global leader in providing products and services for individuals undergoing dialysis, primarily due to chronic kidney disease (CKD). Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in over 120 countries, serving millions of patients while showcasing a commitment to innovation in renal care. By combining advanced medical technologies with a robust network of outpatient dialysis clinics, Fresenius has positioned itself as a vital player in the healthcare sector. Its commitment to high-quality patient care and effective treatment solutions not only sets it apart but also aligns with the increasing global demand for...
Fresenius Medical Care AG & Co KGaA emerged as a global leader in providing products and services for individuals undergoing dialysis, primarily due to chronic kidney disease (CKD). Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in over 120 countries, serving millions of patients while showcasing a commitment to innovation in renal care. By combining advanced medical technologies with a robust network of outpatient dialysis clinics, Fresenius has positioned itself as a vital player in the healthcare sector. Its commitment to high-quality patient care and effective treatment solutions not only sets it apart but also aligns with the increasing global demand for healthcare services, particularly relevant as the world faces an aging population and rising prevalence of kidney-related conditions.
For investors, Fresenius Medical Care represents a compelling opportunity within the expanding healthcare market. The company has demonstrated consistent revenue growth and a resilient business model, generating substantial cash flow, which it reinvests into research and development. This focus on innovation and operational excellence enhances its competitive edge, enabling it to respond swiftly to changes in healthcare regulations and patient needs. With strategic partnerships and integrated care solutions, Fresenius Medical Care is not just navigating the complexities of the healthcare landscape but thriving in it, making it an attractive investment for those looking to enter a sector poised for growth amid increasing global health challenges.
Fresenius Medical Care AG & Co. KGaA is a leading provider of products and services for individuals with renal diseases. The company's core business segments primarily include:
-
Dialysis Products: This segment comprises the development, manufacturing, and marketing of a wide range of dialysis equipment, including hemodialysis machines, dialyzers, and other consumables. These products are essential for treating patients with chronic kidney disease and end-stage renal disease.
-
Dialysis Services: Fresenius provides dialysis services through its network of outpatient dialysis clinics and hospitals. This segment encompasses the management and operation of dialysis centers, offering various treatment options for patients, including in-center hemodialysis, peritoneal dialysis, and home dialysis services.
-
Care Coordination: The company focuses on interoperability and data integration to enhance patient care management, ensuring that patients receive timely and coordinated treatment options. This segment may involve partnerships and collaborations with healthcare providers to optimize care delivery.
-
Renal Pharmaceuticals: Fresenius Medical Care is also involved in the development and distribution of pharmaceuticals that are specifically aimed at patients with kidney disorders. This includes therapies that help manage associated complications of renal diseases.
These core segments are designed to work synergistically, providing comprehensive care to patients with kidney issues while also contributing to the company's robust revenue streams and market position in the healthcare sector.
Fresenius Medical Care AG & Co KGaA, as a leader in the renal care and dialysis market, has several unique competitive advantages that help it maintain a strong position over its rivals:
-
Market Leadership: Fresenius is one of the largest providers of dialysis services and products globally. Its extensive scale allows for better negotiation power with suppliers, economies of scale, and an established reputation.
-
Integrated Business Model: The company operates both as a manufacturer of dialysis products and as a provider of dialysis services. This vertical integration allows for streamlined operations, better quality control, and the ability to innovate quickly based on direct patient care feedback.
-
Extensive Global Network: Fresenius has a vast global presence with thousands of dialysis clinics and partnerships with healthcare providers. This broad reach provides diversified revenue streams and reduces the impact of regional market fluctuations.
-
Strong R&D Capability: With significant investments in research and development, Fresenius fosters innovation in dialysis technologies and treatment protocols. This focus on R&D helps the company stay at the forefront of advancements in renal care.
-
High-Quality Standards and Reputation: The company is known for its commitment to high-quality patient care and safety. Its strong reputation often leads to better partnerships with healthcare systems and physicians, who trust Fresenius products and services.
-
Patient-Centric Approach: Fresenius emphasizes personalized patient care and support services, including education and training for home dialysis patients. This focus on patient needs can lead to higher patient satisfaction and loyalty.
-
Regulatory Expertise: Operating in a highly regulated industry, Fresenius has developed expertise in navigating complex healthcare regulations across different countries, giving it an advantage in compliance and operational efficiency.
-
Strong Financial Stability: The company has a robust financial profile, allowing it to invest in growth opportunities, acquisitions, and technology development while maintaining competitive pricing strategies.
-
Strategic Partnerships and Collaborations: Fresenius has established strategic alliances with hospitals and healthcare organizations, enhancing its capabilities and ensuring a steady referral base for its dialysis services.
-
A Focus on Sustainability: Fresenius is increasingly committed to sustainability and corporate responsibility, addressing social and environmental concerns. This approach appeals to investors and consumers alike, enhancing brand loyalty.
These competitive advantages enable Fresenius Medical Care to differentiate itself in a crowded market, maintain strong operational performance, and deliver value to patients and stakeholders alike.
Fresenius Medical Care AG & Co KGaA, a leading provider of products and services for individuals with renal diseases, faces several risks and challenges in the near future:
-
Regulatory Compliance: The healthcare industry is highly regulated. Changes in regulations, particularly in the U.S. and Europe, could impact operational costs and business models. This includes compliance with FDA regulations, reimbursement policies, and patient safety standards.
-
Market Competition: The dialysis market is competitive, with numerous players offering similar products and services. Increased competition could pressure pricing, market share, and profitability.
-
Technological Advancements: Rapid advancements in medical technology and treatment methodologies, including the development of home dialysis options and wearable technology, require ongoing investment in R&D to remain competitive.
-
Economic Factors: Economic downturns can affect healthcare spending. Additionally, currency fluctuations could impact revenues, especially given the global presence of the company.
-
Supply Chain Disruptions: Like many companies, Fresenius Medical Care could face supply chain issues due to geopolitical tensions, natural disasters, or pandemics. Disruptions can affect the availability of critical components used in dialysis machines and supplies.
-
Litigation Risks: The healthcare sector is prone to litigation due to potential malpractice claims, product liability lawsuits, or regulatory enforcement actions. Legal challenges can lead to significant financial liabilities and reputational damage.
-
Shifts in Reimbursement Models: Changes in how healthcare providers are reimbursed (e.g., value-based care vs. fee-for-service) can impact the financial stability of healthcare providers, including Fresenius, and could alter demand for their services.
-
Healthcare Policy Changes: Ongoing debates around healthcare reform in key markets can create uncertainty that may affect operations, reimbursement rates, and overall demand for dialysis products and services.
-
Aging Population: While the aging population often presents opportunities due to a higher incidence of chronic diseases, it can also increase competition for healthcare resources and elevate costs associated with workforce demands and patient care.
-
Global Health Trends: The rise of chronic diseases beyond renal ailments can shift focus and resources among healthcare providers, demanding flexibility in service offerings.
Addressing these challenges will require strategic planning, innovation, and effective risk management to sustain growth and maintain a competitive edge in the evolving healthcare landscape.
Revenue & Expenses Breakdown
Fresenius Medical Care AG & Co KGaA
Balance Sheet Decomposition
Fresenius Medical Care AG & Co KGaA
Current Assets | 8.7B |
Cash & Short-Term Investments | 1.4B |
Receivables | 4.1B |
Other Current Assets | 3.2B |
Non-Current Assets | 25.2B |
Long-Term Investments | 1.4B |
PP&E | 7.3B |
Intangibles | 16.2B |
Other Non-Current Assets | 409.6m |
Current Liabilities | 5.9B |
Accounts Payable | 783.7m |
Short-Term Debt | 322m |
Other Current Liabilities | 4.8B |
Non-Current Liabilities | 14B |
Long-Term Debt | 10.3B |
Other Non-Current Liabilities | 3.7B |
Earnings Waterfall
Fresenius Medical Care AG & Co KGaA
Revenue
|
19.4B
EUR
|
Cost of Revenue
|
-14.5B
EUR
|
Gross Profit
|
4.9B
EUR
|
Operating Expenses
|
-3.6B
EUR
|
Operating Income
|
1.4B
EUR
|
Other Expenses
|
-828.5m
EUR
|
Net Income
|
530.3m
EUR
|
Free Cash Flow Analysis
Fresenius Medical Care AG & Co KGaA
EUR | |
Free Cash Flow | EUR |
Fresenius Medical Care reported a solid 2% organic revenue growth in Q3, highlighting improved performance in both Care Delivery and Care Enablement despite a slight 0.7% revenue drop due to divestitures. Operating income rose by 10%, achieving a margin of 9.8% as they move towards their 2025 target margin of 10-14%. The company confirmed their 2024 revenue guidance while accelerating their operating income growth forecast to 16-18%. The successful FME25 program yielded EUR 173 million in savings, exceeding their 2024 target. Despite external challenges, the overall outlook remains positive as the company continues to optimize operations and care delivery systems.
What is Earnings Call?
FME Profitability Score
Profitability Due Diligence
Fresenius Medical Care AG & Co KGaA's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
Score
Fresenius Medical Care AG & Co KGaA's profitability score is 48/100. The higher the profitability score, the more profitable the company is.
FME Solvency Score
Solvency Due Diligence
Fresenius Medical Care AG & Co KGaA's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Fresenius Medical Care AG & Co KGaA's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FME Price Targets Summary
Fresenius Medical Care AG & Co KGaA
According to Wall Street analysts, the average 1-year price target for FME is 39.53 EUR with a low forecast of 22.23 EUR and a high forecast of 54.6 EUR.
Dividends
Current shareholder yield for FME is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
FME Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Fresenius Medical Care AG & Co. KgaA provides products and services for individuals with renal diseases. The company is headquartered in Bad Homburg Vor Der Hohe, Hessen and currently employs 122,909 full-time employees. The firm provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The firm also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The firm supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Contact
IPO
Employees
Officers
The intrinsic value of one FME stock under the Base Case scenario is 80.86 EUR.
Compared to the current market price of 42.25 EUR, Fresenius Medical Care AG & Co KGaA is Undervalued by 48%.